Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- SCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- JOURNAL OF DERMATOLOGY50(9) · pp.1180 · 2023
- 피인용
- Web of Science 9Scopus 10
- FWCI (Scopus)
- 1.69
- JCR IF
- JCR 2022 3.1
- ISSN
- 0385-2407
저자
- Jo, Seong Jin제1저자Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Dermatol, Coll Med, Seoul, South Korea
- Huang, Yu-HueiChang Gung Univ, Chang Gung Mem Hosp, Dept Dermatol, Taoyuan, Taiwan
- Tsai, Tsen-FangNatl Taiwan Univ Hosp, Dept Dermatol, Taipei, Taiwan
- 김병수Pusan Natl Univ, Coll Med, Dept Dermatol, Busan, South Korea
- Reich, KristianUniv Med Ctr Hamburg Eppendorf, Inst Hlth Serv Res Dermatol & Nursing, Translat Res Inflammatory Skin Dis, Hamburg, Germany
- Saadoun, CarineDiv Johnson & Johnson Pte Ltd, Reg Med Affairs Janssen Asia Pacific Janssen, Singapore, Singapore
- Chang, Chia-LingDiv Johnson & Johnson Pte Ltd, Reg Med Affairs Janssen Asia Pacific Janssen, Singapore, Singapore
- Yang, Ya-WenJanssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA
- Youn, Sang Woong교신저자Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Dept Dermatol, Coll Med, Seoul, South Korea
초록
Patients with psoriasis were randomized to guselkumab, placebo or adalimumab in the VOYAGE 1 and VOYAGE 2 studies. In this post hoc analysis, difficult-to-treat psoriasis regions in the Asian subpopulation for both the guselkumab and adalimumab groups were compared with placebo at week 16 and the active treatment groups were compared at week 24. Endpoints included patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific Investigator's Global Assessment (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA), and percentage improvement in target Nail Psoriasis Severity Index (NAPSI) score through week 24. Efficacy was also assessed by prior biologic experience at baseline. A total of 199 eligible Asian patients were included. The proportion of patients achieving clear or near clear with guselkumab was superior to adalimumab at week 24 for scalp psoriasis ss-IGA (Asian patients, 72 [85.7%] vs 35 [67.3%], P = 0.004), hands and/or feet psoriasis hf-PGA (29 [82.9%] vs 16 [61.5%], P = 0.054), and similar for fingernail psoriasis f-PGA (28 [63.6%] vs 17 [54.8%], P = 0.412). Guselkumab mean improvements in NAPSI were comparable to adalimumab (39.9% vs 35.9%, P = 0.618). Overall, the complete clearance response of scalp, and hands and/or feet at week 24 occurred in a greater proportion of patients in the guselkumab group, irrespective of baseline biologic status (treatment-naive or treatment-experienced). Guselkumab was superior to adalimumab for the treatment of scalp, and hands and/or feet psoriasis, and proportionally higher for fingernail psoriasis. Findings were comparable to the global study population.
키워드
Asianbiologicsdifficult-to-treatguselkumabpsoriasisPALMOPLANTAR PSORIASISMODERATESCALPPSORIATICS
식별자
- Scopus EID
- 2-s2.0-85163146022
- WoS UID
- 001015600500001



로그인
연구물 목록으로